By pedram1978

Moving Forward Together: MDMA and FDA

Though he admits to feeling like a “grim reaper” at times, Mark Leahey, CEO of the Medical Device Manufacturers Association (MDMA), is “actually an optimist” about the future of the industry. One of the reasons for his optimism is the recent FDA effort of enhanced transparency and accountability led by Christy Foreman, Director of the Office of Device Evaluation (ODE) at the FDA. Last month, Biodesign Alumni sat down with both Leahey and Foreman to discuss their work, challenges, and opportunities for help. Read more